Viridian Therapeutics Inc (VRDN) Stock Analysis

Viridian Therapeutics Inc (VRDN) is a publicly traded company in the HEALTHCARE sector. It trades at $15.87, carries a market capitalization of $1.95B. This page summarizes the public market data, fundamentals, and frequently asked questions for VRDN, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $15.87
• Market Cap: $1.95B
• EPS: $-3.35
• 52-Week High: $34.29
• 52-Week Low: $13.18

Market Sentiment

Viridian Therapeutics Inc currently has a Bullish sentiment score of 0.34.

About Viridian Therapeutics Inc

Viridian Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative therapies for patients suffering from rare and autoimmune disorders. Based in Boulder, Colorado, the company is focused on leveraging advanced research and development to deliver breakthrough treatments that meet significant unmet medical needs. With a strong pipeline of drug candidates and an unwavering commitment to enhancing patient outcomes, Viridian Therapeutics is poised to play a pivotal role ...

GNG Research Analysis

GNG Research scores Viridian Therapeutics Inc (VRDN) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for VRDN.

Frequently Asked Questions

Does VRDN pay dividends?

Viridian Therapeutics Inc (VRDN) does not currently pay a regular dividend.

What is VRDN's market cap?

Viridian Therapeutics Inc (VRDN) has a market capitalization of $1.95B with a current stock price of $15.87.